Georgia imported Vosoritide medicine for medication of rare achondroplasia disease, the Health Ministry confirmed.
Four children diagnosed with achondroplasia will start medication at the initial stage, with others gradually joining the process in 2024.
The medicine will be used at the multi-profile Iashvili Children’s Clinic under tight pediatrician monitoring since the drug may have side effects. The parents will use Vosoritide at home after one month.
Parents of children diagnosed with achondroplasia demanded the import of Vosoritide medicine for many months, holding regular protests.
The Coordination Council for Rare Diseases approved a national management protocol for achondroplasia in July and authorized Vosoritide.
The annual budget for the management of achondroplasia is GEL 34 million.